Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02469376
Other study ID # PET - GP1_1
Secondary ID
Status Terminated
Phase Phase 1
First received June 8, 2015
Last updated May 8, 2017
Start date September 2014
Est. completion date December 1, 2016

Study information

Verified date May 2017
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Arterial and venous thrombi play an important role in various vascular diseases such as myocardial infarction, stroke, transient ischemic attacks (TIA) and pulmonary embolism. These thromboembolic disorders are the leading causes of morbidity and mortality worldwide. A non-invasive method for the quantitative and effective detection of thrombi in the whole body has not yet been established. In spite of the available techniques, 30% to 40% of ischemic strokes "cryptogenic" (undetermined cause, the source of thromboembolism is never identified). Possible causes of cryptogenic stroke atherosclerosis include in the aortic arch or intracranial arteries. A plaque in the arch or other large vessels could be an important source of cryptogenic strokes, however, are those difficult to detect by routine methods. The approach of thrombus targeted molecular imaging could identify potentially troublesome plaques early on before they become a dangerous rupture. The hypothesis is that the radiotracer 18F-arterial GP1 and venous thrombi using positron emission tomography (PET) can be made visible. The primary goal is the potential applicability of the substance as a PET tracer for diagnosing thrombi.


Description:

This is a first in man study with which we are testing the feasibility of the use of this radiopharmaceutical product to visualize a thrombus.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date December 1, 2016
Est. primary completion date December 1, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with AAA (diameter >3.5cm in duplex sonography) or acute DVT.

- Male and female patients 18 years and older,

- Signed Informed Consent after being informed

Exclusion Criteria:

- contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,

- women who are pregnant or breast feeding,

- women with the intention to become pregnant during the course of the study,

- other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease),

- renal clearance < 30 mL/min

- known or suspected non-compliance, drug or alcohol abuse,

- inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject,

- participation in another study with an investigational drug during the present study and 7 days thereafter.

- enrolment of the investigator, his family members, employees and other dependent persons

- last systemic treatment with GP IIb/IIIa antagonists should not have been applied within 48 h before performing study exam

Study Design


Intervention

Drug:
[18F]-GP1
Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.

Locations

Country Name City State
Switzerland University Hospital Zurich, Division of Nuclear Medicine Zurich ZH

Sponsors (2)

Lead Sponsor Collaborator
University of Zurich Piramal Imaging SA

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of biodistribution of [18F]-GP1 and its properties as a PET imaging agent for detection of abdominal aortic aneurysm (AAA) and deep vein thrombosis (DVT). Biodistribution and diagnostic properties of the new Tracer 12 Months
Secondary Calculation of the effective dose to the patient according to the tissue distribution data of [18F]-GP1 (Dosimetry) Dosimtery assessment of the new Tracer 12 Months
See also
  Status Clinical Trial Phase
Recruiting NCT05003843 - BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis N/A
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Withdrawn NCT04136561 - Novel Strategy to Encourage Early Removal of Central Venous Catheters N/A
Completed NCT03420625 - Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02555111 - Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. Phase 3
Completed NCT01975090 - The SENTRY Clinical Study N/A
Completed NCT02037607 - Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Completed NCT00264277 - D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Phase 4
Completed NCT00365950 - 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Phase 4
Completed NCT00182403 - Fixed Dose Heparin Study Phase 3
Completed NCT03682419 - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) N/A
Not yet recruiting NCT04981327 - The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis Phase 3
Recruiting NCT03240120 - A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism Phase 3
Completed NCT03124654 - Development of a Questionnaire to Assess Patient Knowledge About Non-vitamin K Anticoagulants (NOAC) N/A